Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
20,324 results
- Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1): Complete Statistical AnalysisIndependent statistical analysis of Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immune Response Following Seasonal Influenza Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Immune Response Following Seasonal Influenza Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03163342).
- Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings: Complete Statistical AnalysisIndependent statistical analysis of Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease: Complete Statistical AnalysisIndependent statistical analysis of Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immune Responses Induced by Different Licensed Influenza Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Immune Responses Induced by Different Licensed Influenza Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00902278).
- Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant: Complete Statistical AnalysisIndependent statistical analysis of Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01578317).
- Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects: Complete Statistical AnalysisIndependent statistical analysis of Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00706550).
- Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10: Complete Statistical AnalysisIndependent statistical analysis of Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali: Complete Statistical AnalysisIndependent statistical analysis of Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria: Complete Statistical AnalysisIndependent statistical analysis of Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunization To Prevent Acute COPD Exacerbations: Complete Statistical AnalysisIndependent statistical analysis of Immunization To Prevent Acute COPD Exacerbations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03276754).
- Immuno & Safety Study of GSK Biologicals’ Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs: Complete Statistical AnalysisIndependent statistical analysis of Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs: primary endpoint results, effect estimate with confidence interval, sample-size…
- Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients: Complete Statistical AnalysisIndependent statistical analysis of Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immuno-nutrition Supplementation in Haemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Immuno-nutrition Supplementation in Haemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05700851).
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Immunogenicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above: primary endpoint…
- Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety of a Purified Vero Rabies Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of a Purified Vero Rabies Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03145766).
- Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060): Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060): primary endpoint results, effect…
- Immunogenicity and Safety of GlaxoSmithKline Biologicals’ Infanrix™-IPV+Hib Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01309646).
- Immunogenicity and Safety of GSK Biologicals’ Infanrix/Hib in Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00696423).
- Immunogenicity and Safety of GSK Biologicals’ Influenza Vaccine Versus a Licensed Comparator in Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02434770).
- Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer’s Prevenar 13™Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration…
- Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals’ Candidate Influenza Vaccine in Healthy Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe: primary endpoint results, effect estimate…
- Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.: primary endpoint results, effect…
- Immunogenicity and Safety Study of Booster Dose of GSK Biologicals’ IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older: primary endpoint results, effect estimate…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: primary endpoint results,…
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults: primary endpoint results, effect…
- Immunogenicity and Safety Study of GSK Biologicals’ Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF)…
- Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00813904).
- Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Immunogenicity of GSK Biologicals’ Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…